Anti-Vimentin Antibody

from PhosphoSolutions Datasheet Trial Size
5 Citations

Our Anti-Vimentin primary antibody from PhosphoSolutions is chicken polyclonal. It detects human, mouse, and rat Vimentin and is total IgY fraction. It is great for use in WB, IHC, ICC.

Primary Antibody
Bovine, Human, Mouse, Rat
Bovine, Canine, Feline, Goat, Guinea Pig, Hamster, Horse, Non-Human Primate, Rabbit, Sheep, Vole
ICC, IHC, WB
Chicken
Total IgY fraction
VIM
50 kDa

Go to Full Product Details

Immunostaining of tumors and precursor PanIN lesions from 4 week old LSL-KrasG12D; Cdkn2alox/lox; p48Cre (KIC) mice that were treated with 2G8 and/or gemcitabine, Gem. (Anti-Vimentin, cat. 2105-VIM, green; Anti-E-cadherin, red). Photo courtesy of Rolf Brekken, University of Texas Southwestern. CC-BY-4.0
Western blot of NIH 3T3 cell lysate showing specific immunolabeling of the ~50 kDa Vimentin protein.
Immunostaining of HeLa cells labelled with anti-vimentin antibody (cat.2105-VIM, 1:10,000, green), anti-actin (red), and DAPI (blue) labelling of nuclear DNA. The vimentin antibody labels the intermediate filament network while the actin antibody labels the submembranous cytoskeleton, stress fibers, and bundles of actin associated with cell adhesion sites.
Immunostaining of mixed neuron/glial cultures stained with anti-Vimentin antibody (cat. 2105-VIM, 1:500, green) and anti-GFAP antibody (cat.620-GFAP,1:1000, red). Vimentin is expressed alone in fibroblastic and endothelial cells, which are the flattened cells in the middle of the image which appear green. Astrocytes may express primarily GFAP, or GFAP and vimentin, and so appear red (GFAP only) or golden yellow (GFAP and Vimentin).
Immunostaining of tumors and precursor PanIN lesions from 4 week old LSL-KrasG12D; Cdkn2alox/lox; p48Cre (KIC) mice that were treated with 2G8 and/or gemcitabine, Gem. (Anti-Vimentin, cat. 2105-VIM, green; Anti-E-cadherin, red). Photo courtesy of Rolf Brekken, University of Texas Southwestern. CC-BY-4.0
Immunostaining of tumors and precursor PanIN lesions from 4 week old LSL-KrasG12D; Cdkn2alox/lox; p48Cre (KIC) mice that were treated with 2G8 and/or gemcitabine, Gem. (Anti-Vimentin, cat. 2105-VIM, green; Anti-E-cadherin, red). Photo courtesy of Rolf Brekken, University of Texas Southwestern. CC-BY-4.0
Western blot of NIH 3T3 cell lysate showing specific immunolabeling of the ~50 kDa Vimentin protein.
Immunostaining of HeLa cells labelled with anti-vimentin antibody (cat.2105-VIM, 1:10,000, green), anti-actin (red), and DAPI (blue) labelling of nuclear DNA. The vimentin antibody labels the intermediate filament network while the actin antibody labels the submembranous cytoskeleton, stress fibers, and bundles of actin associated with cell adhesion sites.
Immunostaining of mixed neuron/glial cultures stained with anti-Vimentin antibody (cat. 2105-VIM, 1:500, green) and anti-GFAP antibody (cat.620-GFAP,1:1000, red). Vimentin is expressed alone in fibroblastic and endothelial cells, which are the flattened cells in the middle of the image which appear green. Astrocytes may express primarily GFAP, or GFAP and vimentin, and so appear red (GFAP only) or golden yellow (GFAP and Vimentin).

Anti-Vimentin Antibody
SKU: 2105-VIM

Volume: 100 µL
Price:
$360

Bulk Order Anti-Vimentin Antibody

Product Specific References for Applications and Species

  • Immunohistochemistry: Mouse
Immunohistochemistry: Mouse
PMID Dilution Publication
26206560 not listed Kirane, A., et al. 2015. Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. Cancer Research, 75(18), pp.3699-3705.
25060520 not listed Ostapoff, K. T., et al. 2014. Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. Cancer Research, 74(18), 4996-5007.
23696215 not listed Ostapoff, K. T., et al. 2013. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Molecular Cancer Therapeutics, 12(7), pp.1190-1201.
22829202 not listed Kirane, A., et al. 2012. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clinical Cancer Research, 18(18), pp.5031-5042
22678114 not listed Kirane, A., et al. 2012. Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. Carcinogenesis, 33(9), 1639-46.

Related Products

Recently Viewed